Table 1.
Cohort dosing characteristics
| Cohort (Sample Size) | Treatment Duration, wk | Starting Roxadustat Doses | Correction and Maintenance Dosing Frequency | ||
|---|---|---|---|---|---|
| Low Wt, 40–60 kg | Medium Wt, >60–90 kg | Heavy Wt, >90–140 kg | |||
| A (n=24) | 16 | 60 mg | 100 mg | 140 mg | TIW to TIW |
| B (n=24) | 16 | 60 mg | 100 mg | 140 mg | TIW to BIWa |
| C (n=24) | 24 | 50-mg fixed starting dose regardless of weight | TIW to TIW | ||
| D (n=24) | 24 | 100-mg fixed starting dose regardless of weight | TIW to TIW | ||
| E (n=24) | 24 | 70 mg | 100 mg | 150 mg | BIW to QWb |
| F (n=25) | 24 | 70-mg fixed starting dose regardless of weight | TIW to BIW to QWc | ||
Wt, weight; TIW, thrice weekly; BIW, twice weekly; QW, once weekly.
a
Dose frequency reduction from TIW to BIW when hemoglobin response was reached.
b
Dose frequency reduction from BIW to QW when hemoglobin response was reached.
c
Dose frequency reduction from TIW to BIW when hemoglobin response was reached; additional dose frequency reduction from BIW to QW when hemoglobin and dose had been stable for 8 weeks.